Clinical Trial Update: Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Endpoint calibration update for a Phase 2 study of lisinopril in relapsing-remitting multiple sclerosis. The update is associated with Transparency Life Science…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Lisinopril (Lisinopril)

Snippet

Sponsor: Transparency Life Sciences | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: UNKNOWN